Cancer stem cells—allies of the tumor, enemies of the patient

March 6, 2018, University of Extremadura
Scientists of the UEx Molecular Biology of Cancer Research Group want to identify which proteins within the cells are involved in retaining the undifferentiated characteristics of the tumour, which would allow it to be attacked more successfully Credit: UEx

The scientists of the UEx Molecular Biology of Cancer Research Group seek to uncover the physiological mechanisms of cancer stem cells, which are responsible for the progression of the tumour. Thus, they are working on identifying new cell proteins that control cellular differentiation. Cancer stem cells possess the capacity to adopt highly undifferentiated states, characteristic of pluripotent cells, which may contribute to the progression and maintenance of tumour cell types in the same way that a healthy stem cell can give rise to different cell phenotypes. "These cancer stem cells are more resistant to the attack of chemotherapeutic agents. They are capable of regenerating the tumour and helping the tumour cells to spread to other organs," explains Pedro Fernández Salguero, lead researcher on the project.

The deregulation of plays a very important role from an oncological point of view, because it fosters the development of more undifferentiated and aggressive tumours with worse prognosis. "Therefore, we want to identify which proteins within the are involved in retaining the undifferentiated characteristics of the , which would allow it to be attacked more successfully. We also want to identify those leading to differentiated characteristics that reduce tumour development," adds Fernández Salguero.

One specific protein might contribute to keeping the tumour in a more highly undifferentiated state that could affect its metastatic capacity and its response to therapy. The researchers observed that a certain cell protein, the dioxin receptor (Ahr), participates in this process of cellular differentiation. "We have studied lines of derived from patients and analysed tumour markers of potential clinical interest in animal models. The results obtained from both models have been validated in biopsies from patients with and melanoma at the Infanta Cristina Hospital, in Badajoz (Spain)."

In this validation, the investigators found different values for this protein within the tumour and in the non-cancerous tissue from the same patients. They also found that the protein changes its expression in advanced stages, compared with stages prior to the development of the tumour (hepatic cirrhosis or hepatitis, in the case of hepatocellular carcinoma).

Thus, the results point to a therapeutic value for this protein (Ahr) because controlling it might repress the pluripotency of the cancer stem cell and reduce the malignity of the tumour. Naturally occurring molecules have been identified that modulate the activity of this in specific ways. In addition, the dioxin receptor might also facilitate the development of tools for the prognosis and evolution of the types of cancer in the study, hepatocellular carcinoma and melanoma.

Hepatocellular carcinoma is a primary liver cancer distinct from hepatic metastases originated by other tumours. It is highly aggressive and generally has poor prognosis. Further, its incidence is rising—this tumour usually appears as a consequence of an alcoholic liver cirrhosis or an infection by hepatitis B or C. Currently, those suffering from liver have few therapeutic opportunities; one of the few options is a liver transplant. Tools for molecular prognosis and therapeutic targets are very scarce, and the current survival rate for patients with advanced hepatocellular carcinoma is below 10 percent. As a consequence, it is necessary to identify new molecules and therapeutic options complementing the use of surgical resection and the transplant.

Explore further: Potential therapy identified for aggressive breast cancer

More information: Ángel C. Roman et al, The aryl hydrocarbon receptor in the crossroad of signalling networks with therapeutic value, Pharmacology & Therapeutics (2017). DOI: 10.1016/j.pharmthera.2017.12.003

Related Stories

Potential therapy identified for aggressive breast cancer

January 25, 2018
The European Cancer Stem Cell Research Institute, based with Cardiff University, has repurposed a current cancer therapy, TRAIL, to find a new treatment for advanced cancers that are resistant to anti-hormone therapy.

Liver progenitor cells are involved in the development of hepatic tumors

April 18, 2017
The malignant transformation of hepatocytes is the origin of most hepatocellular carcinomas, an aggressive type of liver cancer with high mortality rates. But these cells do not act alone. Research conducted by scientists ...

Potential new therapeutic approach found for liver cell cancer

September 15, 2015
In a recent study, scientists from the Institute for Cancer Research at MedUni Vienna have shown that the growth factor receptor FGFR3 increases the rate of growth and aggressiveness of hepatocellular carcinomas (liver cell ...

Team identifies protein key to cancer cells ability to spread

November 17, 2017
University of Guelph scientists have made a discovery that could reduce the spread of cancer by hindering a protein that binds cancer cells together and allows them to invade tissues.

The cell of origin in childhood brain tumors affects susceptibility to therapy

November 17, 2016
Children that are diagnosed with the severe the brain tumour malignant glioma often have a very poor prognosis. Knowledge about how pediatric malignant glioma arises and develops is still limited. New findings from Uppsala ...

Study discovers proteins which suppress the growth of breast cancer tumors

June 12, 2017
Researchers at the University of Birmingham have found that a type of protein could hold the secret to suppressing the growth of breast cancer tumours.

Recommended for you

Treatment shown to improve the odds against bone marrow cancer

December 15, 2018
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.